 COA |
MSDS |
 HPLC |
NMR |
| CAS No: | 1909226-00-1 |
| Molecular formula(MF) | C24H29N3O4 |
| Molecular Weight(MW): | 423.5 |
| Alias |
| In vitro | DMSO | 84 mg/mL (198.34 mM) |
|---|---|---|
| Ethanol | 5 mg/mL (11.8 mM) | |
| Water | <1 mg/mL | |
| In vivo |
| Description | BDA-366 is a small-molecule Bcl2-BH4 domain antagonist and binds BH4 with high affinity and selectivity. | ||
|---|---|---|---|
| Targets |
|
||
| In vitro |
BDA-366 induces robust apoptosis in MM(Multiple myeloma) cell lines and primary MM cells by inducing BCL2 conformational change. BDA-366 induces a conformational change in the BCL2 molecule that converts it to a death protein, and inhibits lung cancer growth in vitro and in vivo[1]. BDA-366 did not bind to other Bcl2 family members, including Bcl-XL, Mcl-1, or Bfl-1/A1, indicating the specificity of its Bcl2 binding. BDA-366 induces apoptotic cell death in a Bax-dependent manner and induces calcium (Ca2+) release via inhibition of Bcl2/IP3R interaction[2]. |
||
| In vivo | Delivery of BDA-366 substantially suppressed the growth of human MM xenografts in NOD-scid/IL2Rγ null mice, without significant cytotoxic effects on normal hematopoietic cells or body weight[1]. Also, BDA-366 suppresses lung cancer growth via induction of apoptosis in animal models. The BH4 antagonist BDA-366 exhibits potent efficacy against human lung cancer in vivo without platelet reduction[2]. |